Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18–35 Years: A Pooled Database Analysis
Chebib F, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18–35 Years: A Pooled Database Analysis. Kidney Medicine 2024, 100935. DOI: 10.1016/j.xkme.2024.100935.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseMedian follow-upEGFR decline rateFollow-upEGFR declineIncreased risk of rapid progressionAutosomal dominant polycystic kidney disease patientsKidney failureRisk of rapid progressionStandard of care treatmentBenefits of tolvaptanTolvaptan-treated patientsChronic kidney disease stageEfficacy of tolvaptanPolycystic kidney disease progressionEffect of tolvaptanAutosomal dominant polycystic kidney disease progressionKidney disease stageDominant polycystic kidney diseaseLong-term efficacyFollow-up periodKidney disease progressionMayo imaging classificationPolycystic kidney diseaseMixed-effects modelsKidney Stones Account for Increased Imaging Studies in Autosomal Dominant Polycystic Kidney Disease
Simmons K, Ullman L, Dahl N. Kidney Stones Account for Increased Imaging Studies in Autosomal Dominant Polycystic Kidney Disease. Kidney360 2024, 5: 707-714. PMID: 38526140, PMCID: PMC11146651, DOI: 10.34067/kid.0000000000000424.Peer-Reviewed Original ResearchAbdominal imaging studiesChronic kidney diseaseADPKD patientsImaging studiesKidney stonesChronic kidney disease controlKidney diseaseChronic kidney disease groupIncreased incidence of kidney stonesChronic kidney disease populationChronic kidney disease stagePreserved renal functionRetrospectively reviewed patientsAutosomal dominant polycystic kidney diseaseIncidence of kidney stonesDominant polycystic kidney diseaseChi-square and t-testsCoronary artery diseasePolycystic kidney diseaseCompared to controlsCyst complicationsRenal functionChart reviewLower BMIManual chart review